RT Journal Article
T1 The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
A1 Blanco, Jose R
A1 Rivero-Juarez, Antonio
K1 Direct acting antivirals hepatitis c
K1 HCC development
K1 Hepatocellular carcinoma
K1 Interferon-free regimen
K1 Sustained virological response
AB Hepatocellular carcinoma (HCC) is a serious complication inthe natural history of chronic hepatitis C virus (HCV), andcirrhosis is the strongest risk factor [1]. Although differentrandomized clinical trials [2–4], meta-analyses [5–8], and sys-tematic reviews [9] showed the benefits of interferon (IFN) inreducing the risk of HCC, the achievement of the sustainedvirological response (SVR) did not eliminate this risk. This is aninteresting aspect because if HCV infection is associated withchronic inflammation [10], an effective treatment couldresolve the secondary inflammation and the development ofcomplications. However, Yamashita et al. [11] observed that26% of the patients who had a SVR after IFN therapy devel-oped a HCC (the cumulative rates of HCC were 3.1, 10.1, and15.9% at 5, 10, and 15 years, respectively).
PB Taylor & Francis
YR 2016
FD 2016-09-28
LK http://hdl.handle.net/10668/10489
UL http://hdl.handle.net/10668/10489
LA en
NO Blanco JR, Rivero-Juárez A. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it? Expert Rev Anti Infect Ther. 2016 Nov;14(11):993-996
DS RISalud
RD Apr 9, 2025